Anthropic expands AI research into wet lab biology and drug development

Reuters reported on September 18, 2026, that Anthropic has quietly established a wet lab in the San Francisco Bay Area, expanding its AI operations into hands-on biological research and drug science. The lab is part of the company's effort to address real-world experimentation, moving beyond computer simulations. A source confirmed that the lab is not solely focused on drug discovery and declined to provide further details. Anthropic's life sciences head, Eric Kadlecek-Abrams, stated that biological research must be validated through real lab work, aligning with most biotech companies' practices. Kadlecek-Abrams emphasized that the lab represents a step toward tackling diseases overlooked by the pharmaceutical industry. The initiative also aims to maintain public confidence in AI's value before potential job losses or risks emerge. Anthropic CEO Dario Amodei has a personal stake, as his father died from a disease that recently gained a treatment. The company's mission, according to Kadlec-Abrams, is to develop AI that genuinely benefits the world, with life sciences seen as the most promising field for this goal.